Linking Proteomic and Transcriptional Data through the Interactome and Epigenome Reveals a Map of Oncogene-induced Signaling

Cellular signal transduction generally involves cascades of post-translational protein modifications that rapidly catalyze changes in protein-DNA interactions and gene expression. High-throughput measurements are improving our ability to study each of these stages individually, but do not capture the connections between them. Here we present an approach for building a network of physical links among these data that can be used to prioritize targets for pharmacological intervention. Our method recovers the critical missing links between proteomic and transcriptional data by relating changes in chromatin accessibility to changes in expression and then uses these links to connect proteomic and transcriptome data. We applied our approach to integrate epigenomic, phosphoproteomic and transcriptome changes induced by the variant III mutation of the epidermal growth factor receptor (EGFRvIII) in a cell line model of glioblastoma multiforme (GBM). To test the relevance of the network, we used small molecules to target highly connected nodes implicated by the network model that were not detected by the experimental data in isolation and we found that a large fraction of these agents alter cell viability. Among these are two compounds, ICG-001, targeting CREB binding protein (CREBBP), and PKF118–310, targeting β-catenin (CTNNB1), which have not been tested previously for effectiveness against GBM. At the level of transcriptional regulation, we used chromatin immunoprecipitation sequencing (ChIP-Seq) to experimentally determine the genome-wide binding locations of p300, a transcriptional co-regulator highly connected in the network. Analysis of p300 target genes suggested its role in tumorigenesis. We propose that this general method, in which experimental measurements are used as constraints for building regulatory networks from the interactome while taking into account noise and missing data, should be applicable to a wide range of high-throughput datasets.

[1]  D. Rubinsztein,et al.  Huntington's disease: from pathology and genetics to potential therapies. , 2008, The Biochemical journal.

[2]  William Stafford Noble,et al.  Epigenetic priors for identifying active transcription factor binding sites , 2012, Bioinform..

[3]  R. Derynck,et al.  Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. , 2003, The Journal of biological chemistry.

[4]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[5]  Gary D Bader,et al.  PSICQUIC and PSISCORE: accessing and scoring molecular interactions , 2011, Nature Methods.

[6]  Yan Ning,et al.  The Constitutive Activity of Epidermal Growth Factor Receptor vIII Leads to Activation and Differential Trafficking of Wild-type Epidermal Growth Factor Receptor and erbB2 , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  Santosh Kesari,et al.  Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. , 2009, Neuro-oncology.

[8]  Quan Tian,et al.  Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells , 2010, Investigational New Drugs.

[9]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[10]  M. Selbach,et al.  Global quantification of mammalian gene expression control , 2011, Nature.

[11]  Koji Yoshimoto,et al.  Primary Glioblastomas Express Mesenchymal Stem-Like Properties , 2006, Molecular Cancer Research.

[12]  Douglas M. Bates,et al.  Linear mixed model implementation in lme4 , 2013 .

[13]  D. Karger,et al.  Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity , 2009, Nature Genetics.

[14]  V. Tkach,et al.  Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility , 2004, International journal of cancer.

[15]  Geoffrey C Kabat,et al.  Do Steroid Hormones Play a Role in the Etiology of Glioma? , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[16]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. , 2004, Cancer cell.

[17]  Barrett C. Foat,et al.  Profiling condition-specific, genome-wide regulation of mRNA stability in yeast. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Rainer Spang,et al.  Inferring cellular networks – a review , 2007, BMC Bioinformatics.

[19]  Raymond K. Auerbach,et al.  A User's Guide to the Encyclopedia of DNA Elements (ENCODE) , 2011, PLoS biology.

[20]  Harmen J. Bussemaker,et al.  TransfactomeDB: a resource for exploring the nucleotide sequence specificity and condition-specific regulatory activity of trans-acting factors , 2007, Nucleic Acids Res..

[21]  Motoo Nagane,et al.  Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. , 2002, Cancer research.

[22]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[23]  Sheng-Chieh Hsu,et al.  Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.

[24]  Y. Zhang,et al.  IntAct—open source resource for molecular interaction data , 2006, Nucleic Acids Res..

[25]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[26]  Nicola J. Rinaldi,et al.  Transcriptional regulatory code of a eukaryotic genome , 2004, Nature.

[27]  A. Rego,et al.  Mechanisms of neurodegeneration in Huntington’s disease , 2008, European Journal of Neuroscience.

[28]  Paul S Mischel,et al.  Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. , 2009, Cancer research.

[29]  T. Lafortune,et al.  Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma , 2009, Molecular Cancer Therapeutics.

[30]  H. Poulsen,et al.  The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[32]  Matteo Fischetti,et al.  An Algorithmic Framework for the Exact Solution of the Prize-Collecting Steiner Tree Problem , 2006, Math. Program..

[33]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[34]  R. Sharan,et al.  Expander: from expression microarrays to networks and functions , 2010, Nature Protocols.

[35]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[36]  Christopher J Schultz,et al.  Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. , 2006, Neuro-oncology.

[37]  D. di Bernardo,et al.  How to infer gene networks from expression profiles , 2007, Molecular systems biology.

[38]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[39]  Lei Wang,et al.  β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells , 2011, Medical oncology.

[40]  Ronan M. T. Fleming,et al.  Genome-Scale Reconstruction of Escherichia coli's Transcriptional and Translational Machinery: A Knowledge Base, Its Mathematical Formulation, and Its Functional Characterization , 2009, PLoS Comput. Biol..

[41]  William Stafford Noble,et al.  Global mapping of protein-DNA interactions in vivo by digital genomic footprinting , 2009, Nature Methods.

[42]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[43]  V. Jordan,et al.  Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? , 2009, Breast Cancer Research.

[44]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[45]  Li Zhang,et al.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  David E Levy,et al.  Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. , 2008, Genes & development.

[47]  M. Mann,et al.  Defining the transcriptome and proteome in three functionally different human cell lines , 2010, Molecular systems biology.

[48]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[49]  Samuel So,et al.  Small molecule antagonists of Tcf4/β‐catenin complex inhibit the growth of HCC cells in vitro and in vivo , 2010, International journal of cancer.

[50]  Keith L Black,et al.  Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor: Effects on Gene Expression and Growth of Glioma Cells In vitro and In vivo , 2007, Clinical Cancer Research.

[51]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[52]  Caterina Giannini,et al.  Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  Alexandre V. Morozov,et al.  Statistical mechanical modeling of genome-wide transcription factor occupancy data by MatrixREDUCE , 2006, ISMB.

[54]  Michael A. Thomas,et al.  Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. , 2012, Omics : a journal of integrative biology.

[55]  David A Potter,et al.  Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity , 2008, Molecular Cancer Therapeutics.

[56]  Huang Shao,et al.  Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. , 2003, Cancer research.

[57]  Ting Wang,et al.  An improved map of conserved regulatory sites for Saccharomyces cerevisiae , 2006, BMC Bioinformatics.

[58]  E. Fraenkel,et al.  Integrating Proteomic, Transcriptional, and Interactome Data Reveals Hidden Components of Signaling and Regulatory Networks , 2009, Science Signaling.

[59]  E. Levin,et al.  Integration of the extranuclear and nuclear actions of estrogen. , 2005, Molecular endocrinology.

[60]  Xiaodong Jin,et al.  Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations , 2011, Clinical and Experimental Medicine.

[61]  Ernest Fraenkel,et al.  Core transcriptional regulatory circuitry in human hepatocytes , 2006, Molecular systems biology.

[62]  Geraldo Pereira Jotz,et al.  Glutamate Promotes Cell Growth by EGFR Signaling on U-87MG Human Glioblastoma Cell Line , 2010, Pathology & Oncology Research.

[63]  C. Klinge,et al.  Estrogen receptor interaction with co-activators and co-repressors☆ , 2000, Steroids.

[64]  Rory Stark Differential Oestrogen Receptor Binding is Associated with Clinical Outcome in Breast Cancer , 2012, RECOMB.

[65]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[66]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[67]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[68]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[69]  Y. Sakaki,et al.  Phosphoproteome and transcriptome analyses of ErbB ligand-stimulated MCF-7 cells. , 2008, Cancer genomics & proteomics.

[70]  Yanli Wang,et al.  PubChem: a public information system for analyzing bioactivities of small molecules , 2009, Nucleic Acids Res..

[71]  David S. Lapointe,et al.  ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data , 2010, BMC Bioinformatics.

[72]  Michael Platten,et al.  Pathway inhibition: emerging molecular targets for treating glioblastoma. , 2011, Neuro-oncology.

[73]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[74]  Gary D Bader,et al.  BIND--The Biomolecular Interaction Network Database. , 2001, Nucleic acids research.

[75]  Zohar Yakhini,et al.  Discovering Motifs in Ranked Lists of DNA Sequences , 2007, PLoS Comput. Biol..

[76]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  Rudolf Fahlbusch,et al.  Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo , 2005, Journal of neurochemistry.

[78]  Kimmo J Hatanpaa,et al.  Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.

[79]  Yanghua Xiao,et al.  Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma , 2010, BMC Systems Biology.

[80]  Alexander E. Kel,et al.  MATCHTM: a tool for searching transcription factor binding sites in DNA sequences , 2003, Nucleic Acids Res..

[81]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[82]  Takahiro Takano,et al.  Glutamate release promotes growth of malignant gliomas , 2001, Nature Medicine.

[83]  Paul S Mischel,et al.  The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis , 2009, Proceedings of the National Academy of Sciences.

[84]  William Stafford Noble,et al.  Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays , 2006, Nature Methods.

[85]  Wenyan Lu,et al.  Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. , 2009, European journal of pharmacology.

[86]  Daniel Rios,et al.  Ensembl 2011 , 2010, Nucleic Acids Res..

[87]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[88]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[89]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[90]  Hong Ma,et al.  A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[91]  A. Barthel,et al.  Molecular mechanisms of insulin resistance , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[92]  A. Wolffe,et al.  p300 stimulates transcription instigated by ligand‐bound thyroid hormone receptor at a step subsequent to chromatin disruption , 1999, The EMBO journal.

[93]  Ian M. Donaldson,et al.  iRefIndex: A consolidated protein interaction database with provenance , 2008, BMC Bioinformatics.

[94]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[95]  Frank Petersen,et al.  Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex , 2004 .

[96]  Ki-Bum Lee,et al.  Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs. , 2011, Molecular pharmaceutics.

[97]  Brian J. Bennett,et al.  Comparative Analysis of Proteome and Transcriptome Variation in Mouse , 2011, PLoS genetics.

[98]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[99]  Barry Merriman,et al.  U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line , 2010, PLoS genetics.

[100]  Sandhya Rani,et al.  Human Protein Reference Database—2009 update , 2008, Nucleic Acids Res..

[101]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[102]  Michael A. Vogelbaum,et al.  p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation , 2010, Oncotarget.

[103]  J R Feramisco,et al.  Enhanced Tumorigenic Behavior of Glioblastoma Cells Expressing a Truncated Epidermal Growth Factor Receptor Is Mediated through the Ras-Shc-Grb2 Pathway* , 1996, The Journal of Biological Chemistry.

[104]  Bruce Mickey,et al.  EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. , 2009, Cancer research.

[105]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[106]  Nader Sanai,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. , 2010, World neurosurgery.

[107]  J. Streibig,et al.  Bioassay analysis using R , 2005 .

[108]  Mark J. Bowser,et al.  EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[109]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[110]  E. Wingender,et al.  MATCH: A tool for searching transcription factor binding sites in DNA sequences. , 2003, Nucleic acids research.

[111]  Ernest Fraenkel,et al.  Unbiased, Genome-Wide In Vivo Mapping of Transcriptional Regulatory Elements Reveals Sex Differences in Chromatin Structure Associated with Sex-Specific Liver Gene Expression , 2010, Molecular and Cellular Biology.

[112]  Zihai Li,et al.  17 AAG for HSP90 inhibition in cancer--from bench to bedside. , 2009, Current molecular medicine.

[113]  M L Apuzzo,et al.  Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  Forest M White,et al.  Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts* , 2012, Molecular & Cellular Proteomics.

[115]  Jacob F. Degner,et al.  Sequence and Chromatin Accessibility Data Accurate Inference of Transcription Factor Binding from Dna Material Supplemental Open Access , 2022 .

[116]  Eunjee Lee,et al.  Identifying the genetic determinants of transcription factor activity , 2010, Molecular systems biology.

[117]  S. Vandenberg,et al.  EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway , 2012, Oncogene.

[118]  A Guha,et al.  Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.

[119]  J. Hassell,et al.  Small Molecule Antagonists of the Wnt/Beta-Catenin Signaling Pathway Target Breast Tumor-Initiating Cells in a Her2/Neu Mouse Model of Breast Cancer , 2012, PloS one.

[120]  Maria Sjöberg,et al.  Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. , 2005, Molecular endocrinology.

[121]  H. Jiang,et al.  Downregulation of Wnt2 and β-catenin by siRNA suppresses malignant glioma cell growth , 2009, Cancer Gene Therapy.

[122]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[123]  Ernest Fraenkel,et al.  ResponseNet: revealing signaling and regulatory networks linking genetic and transcriptomic screening data , 2011, Nucleic Acids Res..

[124]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[125]  Yan Ning,et al.  Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. , 2005, Cancer research.

[126]  J. Davis Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2007 .